Buprenorphine and related orvinols

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Citations (Scopus)

Abstract

The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.
Original languageEnglish
Title of host publicationResearch and Development of Opioid-Related Ligands
EditorsMei-Chuan Ko, Stephen M Husbands
Place of PublicationWashington, DC
PublisherAmerican Chemical Society
Pages127-144
ISBN (Electronic)9780841227835
ISBN (Print)9780841227828
DOIs
Publication statusPublished - 2013

Publication series

NameACS Symposium Series
PublisherAmerican Chemical Society
Volume1131

Fingerprint Dive into the research topics of 'Buprenorphine and related orvinols'. Together they form a unique fingerprint.

Cite this